Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Gestational Trophoblastic Disease Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The market for gestational trophoblastic disease has seen consistent growth over recent years. Forecasts suggest an expansion from $2.06 billion in 2024 to $2.16 billion by 2025, at a compound annual growth rate (CAGR) of 4.5%. Historically, this growth can be ascribed to elements like public health campaigns, enhanced comprehension of disease pathology, medical research activities and clinical trials, the introduction of targeted therapies, and modifications in treatment guidelines.
The gestational trophoblastic disease market size is anticipated to experience robust expansion over the next few years. It is projected to reach $2.63 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 5.1%. This projected growth can be linked to developments in healthcare infrastructure, the expansion of telemedicine and remote care options, the adoption of patient-centric care strategies, regulatory approvals for innovative treatments, and ongoing genomic and molecular studies. Significant trends anticipated during the forecast period include a move towards personalized medicine, advancements in molecular diagnostics, a heightened focus on immunotherapies and targeted therapies, the integration of digital health technologies, and an increase in awareness and educational programs.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13271&type=smp
Which Drivers Are Impacting The Gestational Trophoblastic Disease Market?
An anticipated increase in abnormal pregnancies is projected to drive expansion within the gestational trophoblastic disease market moving ahead. These are defined as pregnancies that depart from the normal or anticipated trajectory, potentially endangering the health of either the mother, the fetus, or both. Within such abnormal gestations, including molar pregnancies, the trophoblast transforms into a tumor rather than a fetus, leading to gestational trophoblastic disease. As an illustration, data released in May 2024 by the Office for Health Improvement and Disparities, a UK-based government body, indicated 251,377 abortions in 2022 for women in England and Wales. This figure represents the highest count since the Abortion Act’s inception, showing a 17% rise compared to the preceding year. Consequently, the rising occurrence of abnormal pregnancies is fueling the gestational trophoblastic disease market.
What Are The Key Segments In The Gestational Trophoblastic Disease Market?
The gestational trophoblastic diseasemarket covered in this report is segmented –
1) By Type: Hydatidiform Mole; Choriocarcinoma; Placental-Site Trophoblastic Tumor; Epithelioid Trophoblastic Tumor; Other Types
2) By Treatment: Surgery; Chemotherapy; Suction Dilation And Curettage (D&C); Radiation Therapy
3) By End User: Hospital And Clinics; Diagnostic Centers; Other End Users
Subsegments:
1) By Hydatidiform Mole: Complete Hydatidiform Mole; Partial Hydatidiform Mole
2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma; Metastatic Choriocarcinoma
3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation; PSTT With Abnormal Placentation
4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis; Epithelioid Trophoblastic Tumor With Metastasis
5) By Other Types: Trophoblastic Tumor Of Unknown Origin; Non-Gestational Trophoblastic Neoplasia
How Are Emerging Market Trends Shaping The Gestational Trophoblastic Disease Industry Landscape?
Major companies operating within the gestational trophoblastic disease market are implementing frameworks designed to offer dependable services to customers. The introduction of updated guidelines ensures a thorough evaluation of current diagnostic and management strategies for patients with GTD, equipping doctors and nurses with the necessary information to achieve excellence in their care. For example, in May 2022, the Health Service Executive (HSE) National Cancer Control Programme (NCCP), an Ireland-based provider of public health and social care services, launched the revised gestational trophoblastic disease (GTD) guideline at the European organization for the treatment of trophoblastic disease. This guideline integrates the best current research evidence with clinical expertise and patient values, aiming to reduce variations in practice and improve the quality of care delivered.
Which Industry Leaders Are Driving Innovation Across The Gestational Trophoblastic Disease Market?
Major companies operating in the gestational trophoblastic disease market report are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK PLC, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Mylan N.V, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd., Perrigo Company PLC, Jiangsu Hengrui Medicine Co. Ltd., Exelixis Inc., Wockhardt Ltd., Natco Pharma Ltd., Blueprint Medicines Corporation, Array BioPharma Inc., Deciphera Pharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Boston Biomedical Inc., DNAtrix Inc., Arog Pharmaceuticals Inc., Advenchen Laboratories LLC., Mendus AB, AB Science S.A.
Download The Full Report For Exclusive Market Findings:
Which Regional Markets Are Contributing Most To The Gestational Trophoblastic Disease Industry Expansion?
Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2024, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request A Customized Version Of The Gestational Trophoblastic Disease Market Report:
https://www.thebusinessresearchcompany.com/customise?id=13271&type=smp
Browse Through More Reports Similar to the Global Gestational Trophoblastic Disease Market 2025, By The Business Research Company
Diverticulitis Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report
Peripheral Arterial Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/peripheral-arterial-disease-global-market-report
Interstitial Lung Disease Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/interstitial-lung-disease-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model